Compare IVA & INNV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IVA | INNV |
|---|---|---|
| Founded | 2011 | 2007 |
| Country | France | United States |
| Employees | 77 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Nursing Services |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.2B |
| IPO Year | N/A | 2021 |
| Metric | IVA | INNV |
|---|---|---|
| Price | $5.48 | $7.11 |
| Analyst Decision | Strong Buy | Sell |
| Analyst Count | 10 | 1 |
| Target Price | ★ $16.20 | $7.00 |
| AVG Volume (30 Days) | ★ 254.3K | 230.0K |
| Earning Date | 03-30-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $853,699,000.00 |
| Revenue This Year | N/A | $12.85 |
| Revenue Next Year | $751.20 | $8.88 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 11.76 |
| 52 Week Low | $2.94 | $3.13 |
| 52 Week High | $7.98 | $10.69 |
| Indicator | IVA | INNV |
|---|---|---|
| Relative Strength Index (RSI) | 48.36 | 35.77 |
| Support Level | $4.98 | $4.89 |
| Resistance Level | $6.42 | $8.61 |
| Average True Range (ATR) | 0.24 | 0.41 |
| MACD | 0.05 | -0.08 |
| Stochastic Oscillator | 44.54 | 8.92 |
Inventiva SA is a France-based biopharmaceutical company specialized in developing drugs that impact on nuclear receptors, transcription factors and epigenetic modulation. The company is focused on developing its product candidate, lanifibranor, for the treatment of patients with non-alcoholic steatohepatitis, or NASH, a disease for which there are currently no approved therapies. The company is also involved in developing a portfolio of pre-clinical therapy programs. It operates in the segment of Service delivery and clinical stage research, notably into therapies in the areas of oncology, fibrosis, and rare diseases. All the company's operations are in France. Majority of the group's revenue is derived from its research partnerships with AbbVie and BI.
InnovAge Holding Corp is a healthcare delivery platform comprising multiple participants focused on providing all-inclusive, capitated care to high-cost seniors, many of whom are dual-eligible. Its programs are designed to address two of the pressing challenges facing the U.S. healthcare industry: rising costs and poor outcomes. The purpose of the participant-centered care delivery approach is to improve the quality of care participants receive, while keeping them in their homes for as long as possible and reducing the overutilization of high-cost care settings, such as hospitals and nursing homes. The company manages its business as one reportable segment, PACE.